Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index.

[1]  G. Condorelli,et al.  One‐Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus‐Eluting Stents in High Bleeding Risk Patients , 2022, Journal of the American Heart Association.

[2]  A. Kastrati,et al.  Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes , 2021, Clinical Research in Cardiology.

[3]  Deepak L. Bhatt,et al.  Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. , 2021, European heart journal.

[4]  P. Serruys,et al.  P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials , 2021, BMJ.

[5]  Deepak L. Bhatt,et al.  Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. , 2020, Journal of the American College of Cardiology.

[6]  Deepak L. Bhatt,et al.  Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents , 2020, Circulation.

[7]  Y. Jang,et al.  Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. , 2020, JAMA.

[8]  Samin K. Sharma,et al.  Ticagrelor With Aspirin or Alone After Complex PCI: The TWILIGHT-COMPLEX Analysis. , 2020, Journal of the American College of Cardiology.

[9]  M. Price,et al.  Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. , 2020, JACC. Cardiovascular interventions.

[10]  P. Serruys,et al.  The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial , 2020, Clinical Research in Cardiology.

[11]  Samin K. Sharma,et al.  Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.

[12]  N. Cook,et al.  Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials , 2018, The Lancet.

[13]  E. Grove,et al.  Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. , 2018, European heart journal.

[14]  G. Vilahur,et al.  New insights into the role of adipose tissue in thrombosis , 2017, Cardiovascular research.

[15]  D. Tousoulis,et al.  The molecular mechanisms of obesity paradox. , 2017, Cardiovascular research.

[16]  R. Storey,et al.  Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
. , 2017, International journal of clinical pharmacology and therapeutics.

[17]  D. Stanski,et al.  Exposure‐Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction , 2017, Journal of clinical pharmacology.

[18]  J. Manson,et al.  Combined associations of body weight and lifestyle factors with all cause and cause specific mortality in men and women: prospective cohort study , 2016, British Medical Journal.

[19]  V. Beral,et al.  Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents , 2016, The Lancet.

[20]  S. Blair,et al.  Obesity and Cardiovascular Disease , 2006 .

[21]  B. Lacey,et al.  Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. , 2016, Circulation research.

[22]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[23]  T. Powell-Wiley,et al.  Identification of Obesity and Cardiovascular Risk in Ethnically and Racially Diverse Populations: A Scientific Statement From the American Heart Association , 2015, Circulation.

[24]  A. Nordström,et al.  Risk Factors Assessed in Adolescence and the Later Risk of Stroke in Men: A 33-Year Follow-Up Study , 2014, Cerebrovascular Diseases.

[25]  I. Xanthopoulou,et al.  Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. , 2014, American heart journal.

[26]  S. James,et al.  The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study. , 2014, Thrombosis research.

[27]  Masafumi Ueno,et al.  Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease , 2013, Thrombosis and Haemostasis.

[28]  P. Nichelli,et al.  Obesity and the Risk of Intracerebral Hemorrhage: The Multicenter Study on Cerebral Hemorrhage in Italy , 2013, Stroke.

[29]  R. Koppensteiner,et al.  Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. , 2013, Translational research : the journal of laboratory and clinical medicine.

[30]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction , 2013, Nature Reviews Cardiology.

[31]  W. Ruf,et al.  Inflammation, obesity, and thrombosis. , 2012, Blood.

[32]  D. Foley,et al.  Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. , 2012, Journal of the American College of Cardiology.

[33]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[34]  D. Foley,et al.  The role of weight and enteric coating on aspirin response in cardiovascular patients , 2010, Journal of thrombosis and haemostasis : JTH.

[35]  Jonathan E. Dickerson,et al.  Supplementary webappendix , 2013 .

[36]  H. Yatsuya,et al.  Body Mass Index and Risk of Stroke and Myocardial Infarction in a Relatively Lean Population: Meta-Analysis of 16 Japanese Cohorts Using Individual Data , 2010, Circulation. Cardiovascular quality and outcomes.

[37]  Dick M. Goedhart,et al.  The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). , 2010, The American journal of cardiology.

[38]  Jiang He,et al.  Body mass index and risk of stroke among Chinese men and women , 2010, Annals of neurology.

[39]  P. Barragan,et al.  Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. , 2009, The American journal of cardiology.

[40]  A. Skene,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[41]  C. Lavie,et al.  Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. , 2009, Journal of the American College of Cardiology.

[42]  F. Andreotti,et al.  Body fat and cardiovascular risk: understanding the obesity paradox. , 2008, European heart journal.

[43]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[44]  S. Ebrahim,et al.  Body Mass Index and Ischemic and Hemorrhagic Stroke: A Prospective Study in Korean Men , 2004, Stroke.

[45]  C. Macaya,et al.  Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? , 2004, The Journal of invasive cardiology.

[46]  R. Virmani,et al.  Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. , 1998, Circulation.

[47]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.

[48]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.